H1-2021 Presentation 26th August 2021 - | Investor Presentation - Faron Pharmaceuticals
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
H1-2021
Presentation
26 th August 2021
| Investor Presentation
Faron Pharmaceuticals | Non-Confidential Information
Corporate Disclaimer
The contents of this presentation have not been approved by an authorised person within the The contents of this presentation have not been independently verified. The contents of this
meaning of Section 21 of the Financial Services and Markets Act 2000 (as amended) ("FSMA"). presentation are being supplied to you solely for your information and may not be reproduced, re-
Reliance on the contents of this presentation for the purpose of engaging in any investment activity distributed or passed to any other person or published in whole or in part for any purpose. If this
may expose an individual to a significant risk of losing all of the property or other assets invested. document has been received in error, it must be returned immediately to the Company. This
presentation and the information contained herein regarding the Company are strictly confidential
This presentation has been produced by Faron Pharmaceuticals Oy (the “Company” or “Faron”) and and are being shown to you solely for your information. The information may not be reproduced,
has not been, and will not be, reviewed or approved by the Financial Conduct Authority of the distributed to any other person or published, in whole or in part, for any purpose. By receiving this
United Kingdom (“FCA”), London Stock Exchange plc ("LSE"), the Finnish Financial Supervisory presentation, you become bound by the above-referred confidentiality obligation. Failure to comply
Authority or any other authority or regulatory body. with such confidentiality obligation may result in civil, administrative or criminal liabilities.
This presentation does not constitute or form part of any offer for sale or solicitation of any offer to Certain statements included herein express Faron’s expectations or estimates of future performance
buy any securities in the United States or elsewhere nor shall it or any part of it form the basis of or and constitute “Forward-looking Statements”. Forward-looking Statements are necessarily based
be relied on in connection with any contract or commitment to purchase securities. Securities may upon a number of estimates and assumptions that, while considered reasonable by Faron are
not be offered or sold in the United States absent registration or an exemption from registration inherently subject to significant business, economic and competitive uncertainties and
under the Securities Act of 1933, as amended (the “Securities Act”). contingencies. Such Forward-looking Statements involve known and unknown risks, uncertainties
and other factors that may cause the actual financial results, performance or achievements to be
Neither this presentation nor any part of it, nor the fact of its distribution, shall form the basis of, or materially different from estimated future results, performance or achievements expressed or
be relied on in connection with, any contract or investment decision in relation to the Company or implied by those Forward-looking Statements and, as such, the Forward-looking Statements are not
any other entity. guarantees of future performance. Risks include, but are not limited to, that early data from initial
patients in the MATINS trial may not be replicated in larger patient numbers and the outcome of
No undertaking, representation, warranty or other assurance, express or implied, is made or given clinical trials may not be favourable or clinical trials over and above those currently planned may be
by or on behalf of Faron or any its respective directors, officers, partners, employees, agents or required before the Company is able to apply for marketing approval for a product. Faron expressly
advisers or any other person as to the accuracy or completeness of the information or opinions disclaims any intention or obligation to update or revise any Forward-looking Statements whether as
contained in this presentation and no responsibility or liability is accepted by any of them for any a result of new information, events or otherwise. No person is authorised to give any information or
such information or opinions or for any errors, omissions, misstatements or for any other to make any representation other than as contained in this presentation and, if given or made, such
communication written or otherwise. No statement in the presentation is intended to be, nor information or representation must not be relied upon as having been authorised by the Company.
should be construed, as a profit forecast. Neither the Company nor its directors will be obliged to
provide the recipient with access to any additional information or to update this presentation with The foregoing applies to this presentation, any oral presentation of the information in this document
additional information or to correct any inaccuracies which may become apparent. The information by any person on behalf of the Company and any question-and-answer session that follows any such
and opinions contained in this presentation are provided as at the date of this presentation and are oral presentation (collectively, the "Information"). By accepting this presentation, you agree to be
subject to change without notice. bound by the foregoing instructions and limitations in respect of the Information.
2 Faron Pharmaceuticals | Non-Confidential Information
Faron is Focused on Building the Future of Immunotherapy
A unique macrophage focused therapy targeting CLEVER-1 with demonstrated
1
single agent activity in multiple advanced solid tumors
30%+ clinical benefit positions macrophage-targeting Bexmarilimab to
2
change the treatment paradigm in difficult to treat cancers
Favorable safety profile of Bexmarilimab allows for further expansion
3
and dose confirmation trials
Worldwide rights to all indications for Bexmarilimab with strong
4
IP coverage through at least 2037
5 Multiple near-term value inflection points in the next 18 months for Bexmarilimab
Other macrophage targets (e.g., CD47) attract significant attention from
6
investors and pharma companies
Additional pipeline assets focused on organ protection and regenerative medicine
7
show early signs of preclinical and clinical efficacy
3 Faron Pharmaceuticals | Non-Confidential Information
Harness the Power of the Immune System
Modulating the immune system is key to tackling cancer and inflammation
Programs Phase of Development Anticipated
Indication(s)
(Target) Preclinical Phase 1 Phase 2 Phase 3 Key Milestones
Immuno-Oncology Additional data to be presented at ESMO
Solid Tumors (MATINS) Congress 2021 in September
Pivotal cohorts to begin recruitment H1 ’22
NSCLC
First-patient-in expected in Q4 ‘21
Bexmarilimab (MATINS-05 LUNG)
(anti-CLEVER-1 mAb)
Neoadjuvant in Solid Tumors
First-patient-in expected in Q4 ‘21
(RENACOL)
Hematological Malignancies First-patient-in expected in Q4 ‘21
(MATINAML) Phase 1 data in Q3 ’22
Organ Protection
ARDS & COVID-19
First patient dosed August ‘21
(HIBISCUS)
Traumakine
(Intravenous IFN ARDS & COVID-19
beta-1a) Additional data expected in '21
(REMAP-CAP)
Regenerative Medicine Hematological
Malignancies
Haematokine Anticipated IND submission in 2022
(A0C3 Inhibitor) Bone Marrow Failure
4 Faron Pharmaceuticals | Non-Confidential Information
Pipeline Highligths
H1-2021 and post period
• Bexmarilimab demonstrates compelling antitumor activity in multiple advanced solid tumor types in
the completed Part I and ongoing Part II of the MATINS study
• Strongest results were observed in cutaneous melanoma, gastric cancer, cholangiocarcinoma, and
hepatocellular carcinoma, with a 30% - 40% disease control rate across these tumor types
• Additional clinical trials are planned to start in Q4 2021
• Secured patents in the US and Japan protecting the composition of matter of bexmarilimab
• Companion diagnostics (CDx) for Clever-1 detection in histological samples developed and validated with
Laboratory Corporation of America (“Labcorp”)
• Additional MATINS data accepted as LBA for presentation at ESMO Congress 2021 in mid-September
• Traumakine® development accelerated for the treatment of acute respiratory distress syndrome (ARDS)
and other ischemic or hyperinflammatory conditions.
• Dosing commenced in the Phase II/III HIBISCUS trial – co-funded by US Department of Defense
• Signed a sub-license agreement covering a relevant manufacturing patent in the US
• Partnership established with the 59th Medical Wing of the U.S. Air Force and U.S. Army and U.S. Army Institute
of Surgical Research to explore the use of Traumakine for organ protection in combat wounds
• New manufacturing process is progressing as planned in collaboration with AGC Biologics.
5 | 08.26.21 Faron Pharmaceuticals | Non-Confidential Information
Financial Highlights
1 January – 30 June 2021 (unaudited)
• Cash balances of €7.0 million at 30 June 2021 (2020: €11.6 million).
• Operating loss of €10.4 million for the six months ended 30 June 2021 (2020: €7.1 million). The
increase mainly driven by an additional €3.5m million in R&D expenses due to acceleration of the
pipeline assets
• Net assets of €2.8 million at 30 June 2021 (2020: €7.3 million).
• Strengthened the balance sheet in February 2021 by raising €15 million gross (€14.4 million net)
from new and existing shareholders through an issuance of 3,521,127 new ordinary shares.
• Received $6.1 million commitment from the US Department of Defense (DoD) to support the
HIBISCUS trial as part of the Coronavirus Aid, Relief, and Economic Security (CARES) Act
6 | 26 August 2021 Faron Pharmaceuticals | Non-Confidential Information
Bexmarilimab
(anti-CLEVER-1 mAb)
| Investor Presentation
Faron Pharmaceuticals | Non-Confidential Information
A CLEVER Antibody: Outsmarting Cancer with Early Signs of Efficacy
A unique macrophage focused therapy targeting CLEVER-1
1 with demonstrated single agent activity in multiple advanced
solid tumors
Favorable safety profile enables extensive combinations with
2 checkpoint inhibitors
Opportunity to transform the treatment of cancers that are
3 not responsive to current treatment options
Extensive IP Coverage through 2037 with further protection
4
being sought via regulatory designations
8 Faron Pharmaceuticals | Non-Confidential Information
Bexmarilimab Opportunity
Benefiting those who do not respond to checkpoint inhibition
CPIs were among the first drugs to significantly impact survival in
metastatic melanoma and lung cancer, which were in-curable before The adoption of CPIs has occurred very quickly due to their success
this in improving overall survival, despite poor response rates1
All Comers
Responders
13%
87%
Non-Responders
Kaplan-Meier Curver from: KEYNOTE-407 Pembrolizumab and Chemotherapy for NSCLC 1) O’Connor et al. (2018) JAMA Oncol.;4(8):e180798.
Paz-Ares. et al. (2018) NEJM. 379: 2040-2051
Pie Chart adapted from: Haslam and Prasad (2019) JAMA Netw Open. 2019 May;
9 2(5): e192535.
Faron Pharmaceuticals | Non-Confidential Information
Macrophages: The Next Breakthrough in Oncology
A poorly understood, but promising area of IO 1
Why Macrophages? Macrophages make up nearly 50% of cancer mass 7
• Macrophages promote tumor growth and metastases M2, but not M1 macrophages play a central role in promoting
proliferation, colony formation, migration and treatment resistance 5
• Macrophages create a highly immunosuppressive environment
• Targeting tumor associated macrophages (TAMs) has shown
promising preclinical results 1,2
CRC
• Continued evidence shows that macrophages are key in
treatment resistance 3
• Repolarisation of pro-tumoral M2 macrophages to anti-tumor
M1 macrophages causes a tumor suppressive effect 3,4
• Activating macrophages has shown to remove resistance against
Melanoma
the current regime of targeted therapies across indications 4,5,6
1) Jahchan et al (2019) Front Immunology. 10:1611
2) Cassetta and Pollard (2018) Nature Reviews: Drug Discovery 17(12) 887-904
3) Guerriero (2018) Trends in Molecular Medicine. 24 (5) 472-489
4) Duan & Luo (2021) Signal Trans and Targ. Ther. 6 (127) Tumors high in macrophages impede the entrance of effector T-
5)
6)
Dong et al (2019) BJC. 121 22-33
Peranzoni et al (2018) PNAS. 115 (17) E4041-4050
cells limiting the effect of current checkpoints therapies 6
7) Vinogradov et al (2014) Nanomedicine. 9(5) 695-707
8) Virtakoivu et al. (2021) Clin Cancer Res June 2, 2021, DOI: 10.1158/1078- Tumor samples from MATINS Patients 8
0432.CCR-20-4862
10 Faron Pharmaceuticals | Non-Confidential InformationCDx (Companion Diagnostics) for Clever-1 Detection in Tissue Samples
Significant milestone achieved
• Clone identification and initial characterization
• Protocol
• Accuracy, Precision, Sensitivity, Specificity
-> Laboratory Developed Test (LDT) is working, and clinical trial testing & feasibility assessment can be initiated
• Next steps
– Manufacturing capability for reagents/kits
– Partnerships with IVD manufacturers
– FDA submissions
– Commercialization
– Market access strategy, product launch and reimbursement strategy
11 | 08.26.21 Faron Pharmaceuticals | Non-Confidential InformationThe Most Promising Macrophage Strategy: Reprogramming 1
Novel and diverse antibody with broad applicability
Bexmarilimab
CLEVER-1
Bexmarilimab is a humanised anti-CLEVER-1 IgG4 antibody currently in clinical trials
• A large glycoprotein receptor that is expressed on the for solid tumors and expanding into hematological malignancies. 2
surface of immunosuppressive macrophages 2
Faron holds the worldwide rights to the Bexmarilimab program in all indications.
• As a scavenger receptor it is known to bind to a wide range of Proposed mechanism of action
ligands and therefore central to tissue homoeostasis and
tolerance 2
• CLEVER-1 positive macrophages are highly
immunosuppressive; high expression levels are only seen in
cancer and pregnancy 3
• CLEVER-1 has been shown to be central to treatment
resistance in both solid and liquid tumors alike 4,5,6,7
• CLEVER-1 is a multifaceted molecule with a major impact on
tumor immune response 2
1) Li et al (2021) JITC. 9: e001341
2) Hollmen et al., (2020) BJC. 123. 501-509
3) Palani et al., (2011) Eur. J. Immunol. 41 2052-2063
4) Kwon et al., (2019) Head Neck. 41 2058-2064 Bexmarilimab
5) Yin et al., (2020) Oncol. Lett. 19(3)2404-2412
6) Dong et al (2019) BJC. 121 22-33
7) Lin et al (2019) Mol. Ther. Nuc. Acids. 18 476-484
12 Faron Pharmaceuticals | Non-Confidential InformationCLEVER-1: a Master T Cell Suppressor
Tackling both immunosuppressive macrophages and soluble protein that inactivates T-cells
Advanced cancer
patients have
elevated levels of
Bexmarilimab CLEVER-1
macrophages and
the soluble form
Bexmarilimab inhibits soluble CLEVER-1 from
interfering with the immunological synapse and
T-cell activation, a tool for cancer to create
systemic immune suppression
13 Faron Pharmaceuticals | Non-Confidential InformationInhibition of CLEVER-1 Leads to Responses in Refractory Mice Models
Macrophages are central to tumor growth and survival
Silencing the STAB1 gene for CLEVER-1 shows a dramatic improvement in AML cell lines
*
*
* 500 LLC 1
400 2
300
*
*
mm3
200
100
Tumors cannot grow in mice that do not have 00
5 10 15
CLEVER-1 positive macrophages 1
Days
Anti-CLEVER-1 has single agent activity in anti-PD-1 refractory models such as LLC and B16 1,2
1) Viitala et al. (2019) Clin Cancer Res. 25(11) 2) Karikoski et al. (2014) Clin. Cancer Res. 20(24)
14 Faron Pharmaceuticals | Non-Confidential InformationBexmarilimab’s Ability to Turn Cold Tumors Hot
23% of immune suppressed cancer patients show an IFNy response during dose finding
Robust T-Cell Restoration of Pro-Inflammatory
Mice 1 MATINS patient 2 Activation 2 IFNy Response 2
Pre-
Wild Type
Treatment IFNy
Post-
CLEVER KO Treatment
Cytotoxic granzyme B positive CD8 T cells can be seen in
green and red
1) Viitala et al. (2019) Clin Cancer Res. 25(11)
2) Virtakoivu et al. (2021) Clin Cancer Res June 2 2021 DOI: 10.1158/1078-0432.CCR-20-4862
15 Faron Pharmaceuticals | Non-Confidential InformationMATINS Trial Design and Rationale
A first-in-human study in advanced solid tumors with high levels of macrophages
Design
Biology Milestones
Macrophages are central for changing the Open-label Phase 1/2 adaptive clinical
treatment paradigm in IO 1 trial in selected metastatic or
inoperable solid tumors 5 Additional data from Phase 1/2 trial to be
CLEVER-1 is a prognostic marker for multiple
presented at ESMO Congress 2021 in
solid tumors 2,3,4,5 Currently evaluating multiple doses September
and frequencies including 1W, 2W and
CLEVER-1 has multiple functions that are key to 3W dosing for optimal target coverage
fighting tumors 1,6 First Pivotal Cohorts to begin recruitment
H1 2022
Tumor-associated M2 macrophages can make Focus on advanced hard-to-treat solid
up to 50% of the tumor mass 7 cancers with exhausted treatment
options 5
Companion Diagnostics will be incorporated into the pivotal expansion of the cohorts into larger trials and larger indications where patient
populations are very heterogenic. The current plan is to evaluate IHC, sCLEVER-1 and other T-cell activation markers.
1) Duan & Luo (2021) Signal Trans and Targ. Ther. 6 (127) 2) Kwon et al., (2019) Head Neck. 41 2058-2064 3) Yin et al., (2020) Oncol. Lett. 19(3)2404-2412 4) Zhao et al (2019) J. Canc. Res.
& Clin. Onco. 145:3005-3019 5) Dong et al (2019) BJC. 121 22-33 6) Hollmen et al., (2020) BJC. 123. 501-509 7) Vinogradov et al., (2014) Nanomedicine. 9(5) 695-707
16 Faron Pharmaceuticals | Non-Confidential InformationA Dramatic Turnaround for Last Line Patients
Overall survival in all MATINS patients
Patients who are at the end of life have a
significant survival benefit
• In all comers, last line, unoptimized setting patients with
cutaneous melanoma, gastric cancer, cholangiocarcinoma and
hepatocellular carcinoma disease control was seen in up to 30
- 40% of patients 1,2
• Patients who benefit (PR or SD) from Bexmarilimab have 100%
6-month survival estimate 3
• Compared to 30% survival in non-responding patients
• This almost doubled the survival of advance
cholangiocarcinoma patients, when comparing
to historical survival 4
• Progression free survival was the same in non-responding and
Response to Bexmarilimab –treatment responding patients prior to treatment with Bexmarilimab
Non-responders Responders Data available from company press release 1,2,3
1)Faron Pharmaceuticals Ltd (2021 May 17th) Bexmarilimab monotherapy shows promising anti-tumour activity in multiple advanced solid tumours. [Press release] https://www.faron.com/news-
events/news-and-press-releases?rnsid=1476431&cid=2223 2) Faron Pharmaceuticals Ltd (2021 June 22nd) Updated corporate presentation 3) Faron Pharmaceuticals Ltd (2021 March 22nd)
Bexmarilimab (Clevegen) development update. [Press release] https://www.faron.com/news-events/news-and-press-releases?rnsid=1462608&cid=2223 4) Smyth and Moehler (2019) Ther Adv Med Oncol.
17 | 26 August, 2021 Faron Pharmaceuticals | Non-Confidential InformationMATINS Phase I/II Top Line Data
Safety and efficacy data from over 140 patients
Top Line Efficacy Data Subsequent expansion and dose confirmation cohorts
Response in based on the responses seen in first 10
target lesion (%) patients/indications include:
Gastric cancer, cutaneous melanoma,
cholangiocarcinoma and hepatocellular carcinoma
*Part I patient with tumor shrinkage but hemorrhagic brain metastases leading to PD
18 of treatment
EOT = end Faron Pharmaceuticals | Non-Confidential InformationSoluble CLEVER-1: a Master Regulator of T Cell Activation
Bexmarilimab treatment downregulates major checkpoints
PD-1 Levels
in Patients What makes Bexmarilimab
different?
CD4 Cells
Dosing Unique macrophage focused therapy
to show signs of survival benefit in
multiple advanced cancer types as a
monotherapy
Ability to specifically target and
reprogram immunosuppressive M2
macrophages
CD8 Cells
Transformative effect on T cells by
targeting macrophages; increasing
T cell activity and improving their
Level of active sCLEVER-1 during Bexmarilimab cytotoxic effectiveness
treatment
The downward trend in expression of major checkpoints aligns with the inhibition of soluble
CLEVER-1
19 Faron Pharmaceuticals | Non-Confidential InformationIndications Chosen for MATINS Expansion
Response Rates, Patient Populations and Annual Incidence
Standard of Care and Bexmarilimab benefit in Refractory
Annual Incidence 1
Refractory Population Population 10,11,12
USA: 98,000
5EU: 77,500 CPIs as standard of care at 1stL 30%
Cutaneous Melanoma
Japan: 13,000 60-70% refractory to 1stL 2,3 (3/10)
China: 9,500
USA: 29,500
5EU: 54,000 3rdL approval 4 30%
Gastric Cancer
Japan: 140,500 80% refractory to 3rdL CPIs 5,6 (3/10)
China: 478,500
USA: 10,500
1stL generic chemotherapy
5EU: 4,000 30%
Cholangiocarcinoma No established 2ndL 7
Japan: 7,500 (3/10)
85% refractory to CPI treatment 8
China: 48,000
USA: 34 500
Recent approval 1stL SOC to
Hepatocellular 5EU: 43 500 40%
Atezolizumab–Bevacizumab (PD1-VEGF)
Carcinoma Japan: 30 500 (4/10)
75% refractory to combo treatment 9
China: 167 500
1) GlobalData Epidemiology and Market Size Database 2) Asher et al (2020) Cancers. 12 (8) 2329; 3) Hamid et al (2019) Ann. Onco. 30(4) 582-588; 4) Le et al (2020) CCC. 19(1) 32-38; 5) Magalhaes et al (2018) Can J Gastro
Hepatol 2018; 6) Brar and Shah (2019) Ther Adv Gastro 12; 7) Saeed et al (2019) CCR 18(2); 8) Guo and Shen (2020) Onco. Letters 20(6) 9) Finn et al (2020) NEJM. 382: 1894-1905
10)Faron Pharmaceuticals Ltd (2021 May 17th) Bexmarilimab monotherapy shows promising anti-tumour activity in multiple advanced solid tumours. [Press release] https://www.faron.com/news-events/news-and-
press-releases?rnsid=1476431&cid=2223 11) Faron Pharmaceuticals Ltd (2021 March 22nd) Bexmarilimab (Clevegen) development update. [Press release] https://www.faron.com/news-events/news-and-press-
releases?rnsid=1462608&cid=2223 12) Faron Pharmaceuticals Ltd (2021 June 22nd) Updated corporate presentation 13) xxxxxxx
20 | 08.26.21 Faron Pharmaceuticals | Non-Confidential InformationBexmarilimab Clinical Development Plan in Solid Tumors
Following the well-established path of other immuno-oncology drugs
Today FDA
Exploring meeting
Pivotal Expansion BLA
Dose Confirmation
indications & doses
Once Bexmarilimab has
shown a potential therapeutic One or two doses will go into
benefit in a given indication a final pivotal expansion as pre- Conditional approval
multiple dose and frequency defined in an FDA meeting for indication
expansion will be conducted
An All Comers Platform Trial
29 patients/group 50 - 100 patients/group
Investigating dose and frequency
prior to moving it into pivotal
expansion cohorts
Promising cancers Up to 4 different doses 1 to 2 doses will be
One dose for
expanded from the & frequencies are evaluated in pivotal
approval
MATINS platform typically evaluated expansion
Q3-2021 Q1-2022 2023
A similar strategy has been successfully utilised by major checkpoints,
such as Keytruda, Opdivo and Yervoy
Faron Pharmaceuticals | Non-Confidential InformationBexmarilimab Clinical Development Plan
Evidence based clinical trials to allow for registration
2021 2022 2023 2024 Sites Involved
The MATINS Platform Trial 1,2
Comprehensive
Cancer Centre
Gastric
Melanoma
Solid tumors
Cholangiocarcinoma
Hepatocellular carcinoma
Neo-adjuvant study in multiple indications 2
NSCLC in 1st line with a PD-1 inhibitor 2,3,4
Hematological
malignancies
Ph I/II AML & MDS 1,2 Pivotal Study in AML & MDS 2,4
1) Open label adaptive trials aiming to become pivotal studies
2) These trials are Faron’s future plans and therefore subject to changes depending on multiple factors
3) Investigator sponsored study design
4) RCT in combination with first line standard of care (SOC)
Faron Pharmaceuticals | Non-Confidential InformationHOT or COLD Tumor - Can RENACOL Answer That?
Testing neoadjuvant bexmarilimab treatment in localized renal cell and colon carcinoma
Target: Localized renal cell and colon carcinoma
prior surgical tumor removal
Dosing: Single dosing 1-10 mg/kg (with option to
go up 30 or 100 mg/kg) two weeks prior surgical
operation
Tumor analysis: Can we reinvigorate healthy
immune system against cancer?
• Pathological response (tumour necrosis)
• Immune cell (T-cell) migration into the tissue
• DC migration (collection of lymph nodes)
• Gene expression in tissues
• Efficacy (DFS; 1, 3 & 5 yrs)
Safety: Focus on complications after surgery e.g., Bexmarilimab 25 mg/ml Checkpoint
wound healing concenrate for solution inhibitors
for infusion
23 | 08.26.21 Faron Pharmaceuticals | Non-Confidential InformationFaron is Focused on Building the Future of Immunotherapy
A unique macrophage focused therapy targeting CLEVER-1 with demonstrated
1
single agent activity in multiple advanced solid tumors
30%+ clinical benefit positions macrophage-targeting Bexmarilimab to
2
change the treatment paradigm in difficult to treat cancers
Favorable safety profile of Bexmarilimab allows for further expansion
3
and dose confirmation trials
Worldwide rights to all indications for Bexmarilimab with strong
4
IP coverage through at least 2037
5 Multiple near-term value inflection points in the next 18 months for Bexmarilimab
Other macrophage targets (e.g., CD47) attract significant attention from
6
investors and pharma companies
Additional pipeline assets focused on organ protection and regenerative medicine
7
show early signs of preclinical and clinical efficacy
24 Faron Pharmaceuticals | Non-Confidential InformationTraumakine
(Intravenous IFN beta-1a)
| Investor Presentation
Faron Pharmaceuticals | Non-Confidential InformationInterferon Beta Induces CD73 for Organ Protection
An effective pharmacotherapy for producing anti-inflammatory adenosine
Pro-inflammatory Anti-inflammatory
Capillary Alveolus ATP AMP Adenosine
Capillary
CO2 O2 Alveolus
Protein-rich fluid Normal
CO2 O2 Red
O2 CO 2 blood
cells
Red blood cells AMP
Capillary leakage Leukocyte CD39 CD73 Adenosine Interferon CD73 Leukocyte
β expression
Maximising the upside potential of a blockbuster
• In Comparison with Dexamethasone
• First patient in Q3 2021
26 Faron Pharmaceuticals | Non-Confidential InformationHIBISCUS: A Phase 2/3 Co-funded by the Department of Defence
Supporting Hospitalised COVID-19 Patients to prevent ARDS and admission to the ICU
Phase 2 Phase 3
Interim Analysis
Traumakine
better than Adjust
dexamethasone powering
according to
interim results
Require No
and continue
Mechanical
Randomization Interim Analysis enrolment
Ventilation at 70 Patients
?
1:1
COVID-19 patients Traumakine:
Yes
needing hospitalization Dexamethasone
and supplemental Patient requires
oxygen
Stop the trial
steroids and is for futility
excluded from
the trial
The HIBISCUS Trial in the US: Primary end-point: Clinical Status at D14 Fueillet et al. 2021
An RCT, which aims to prove the superiority Secondary end-points: Mortality at D28, ICUfree days at D28, Ventilation free Days
of Traumakine against current standard of
care (dexamethasone) when given early in Size of Phase II: 140 patients
hospitalized COVID-19 patients who do not The use of steroids concomitantly is not allowed, but steroids can be used after IFN beta
yet require mechanical ventilation
The first COVID trial to assess the sequenced use of two immunomodulatory agents (IFN beta & steroids)
27 | 26 August 2021 Faron Pharmaceuticals | Non-Confidential InformationCorporate Highlights
| Investor Presentation
Faron Pharmaceuticals | Non-Confidential InformationA push towards approval
1 Single agent activity in multiple solid tumors which are refractory to standard of care
2 We see a significant clinical benefit in an all comers setting
3 HCC 1st line recent SOC with 75% refractory to combo treatment
4 2nd Line Melanoma is forecast to be 1 Bn by 2026 from 20,000 patients
3rd Line Gastric is likely to have a CAGR of 600% in Western Markets
5
over the next 5 years with 22% ORR
Cholangiocarcinoma currently has a limited market size
6
due to no innovative drug approval
CPIs have been approved with similar sized trials (Approx. n. 100-200 patients)
7
with low ORR (10-20%)
29 Faron Pharmaceuticals | Non-Confidential InformationMultiple Near-Term Catalysts For Bexmarilimab
Discovery of Soluble CLEVER
CMC Commercial Scale Preparation
Topline data from MATINS Phase 1
Dramatic Survival Benefit was seen in responding patients
Selection of Expansion Cohorts (Gastric, Melanoma and Cholangiocarcinoma)
Key Intellectual Property (Confirmation of Matter) Awarded
Major Publication of Phase 1 Data in Clinical Cancer Research
Additional data release on MATINS solid tumors in Q3 ’21
Confirmation of final dosage and frequency for pivotal expansion
FDA Meeting for pivotal expansion
Pivotal cohorts to begin recruitment in H1 ’22
First-patient-in for neo-adjuvant (RENACOL) study in Q4’21
First-patient-in for hematological malignancies in Q4’21
Phase 1 data in Q3 ’22
Investigator Initiated trials to begin
Anti-PD-1 combination
30 | 26 August 2021 Faron Pharmaceuticals | Non-Confidential InformationAnd Across Entire Pipeline
CMC Commercial Scale Preparation
HIBISCUS first patient dosed
Traumakine Interim analysis
Poster Presentation at Military Health System Research Symposium
REMAP-CAP Interim Readout
Organ protection data release with the DoD
Ongoing pre-clinical studies with humanized AOC3 mice and
with ex vivo human cells
Haematokine
Clinical Development plan to be announced
Anticipated IND submission in 2022
31 | 26 August 2021 Faron Pharmaceuticals | Non-Confidential InformationThank you
| Investor Presentation
Faron Pharmaceuticals | Non-Confidential InformationYou can also read
